We can’t show the full text here under this license. Use the link below to read it at the source.
Lower cardiorenal risk with sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study
Lower heart and kidney risk with sodium-glucose cotransporter-2 inhibitors compared to dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients without existing heart or kidney disease
AI simplified
Abstract
SGLT2 inhibitors were associated with a lower risk of cardiorenal disease and heart failure in 105,130 patients with type 2 diabetes.
- Patients treated with SGLT2 inhibitors had a hazard ratio of 0.56 for developing cardiorenal disease compared to those on DPP4 inhibitors.
- The risk of heart failure in patients using SGLT2 inhibitors was reduced, with a hazard ratio of 0.71.
- Chronic kidney disease risk was significantly lower in the SGLT2 group, with a hazard ratio of 0.44.
- SGLT2 inhibitors were also associated with decreased all-cause mortality (HR 0.67) and cardiovascular mortality (HR 0.61).
- No significant differences were found for stroke (HR 0.87) and myocardial infarction (HR 0.94) between the treatment groups.
AI simplified
Key numbers
0.44
Decrease in CKD Risk
Hazard ratio for CKD in SGLT2i vs. DPP4i
0.71
Decrease in HF Risk
Hazard ratio for heart failure in SGLT2i vs. DPP4i
0.67
Decrease in All-Cause Mortality Risk
Hazard ratio for all-cause mortality in SGLT2i vs. DPP4i